| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02519335 | Heart Defects, Congenital | Drug: Dexrazoxane | Medical City Children's Hospital|Mylan Pharmaceuticals | Phase 1 | 2014-09-01 | 2017-03-21 |
| NCT00955890 | Breast Cancer | Drug: Dexrazoxane hydrochloride|Drug: Dexrazoxane hydrochloride | Fudan University | Phase 2 | 2009-06-01 | 2012-02-27 |
| NCT01596088 | Extravasations of Anthracycline Anti-cancer Agents | Drug: Dexrazoxane | Kissei Pharmaceutical Co., Ltd. | Phase 1|Phase 2 | null | 2015-03-18 |
| NCT02584309 | Sarcoma, Soft Tissue|Soft Tissue Sarcoma|Undifferentiated Pleomorphic Sarcoma|Leiomyosarcoma|Liposarcoma|Synovial Sarcoma|Myxofibrosarcoma|Angiosarcoma|Fibrosarcoma|Malignant Peripheral Nerve Sheath Tumor|Epithelioid Sarcoma | Drug: Dexrazoxane|Drug: Doxorubicin|Drug: Olaratumab | Washington University School of Medicine | Phase 2 | 2016-02-22 | 2017-02-14 |
| NCT01627938 | Multiple Sclerosis | Drug: Dexrazoxane (DRZ) plus Mitoxantrone (MX)|Drug: Placebo plus Mitoxantrone (MX) | PD Dr. Andrew Chan|Ruhr University of Bochum | Phase 2 | 2012-04-01 | 2014-11-04 |
| NCT00933985 | Acute Leukemias of Ambiguous Lineage|Acute Undifferentiated Leukemia|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Relapsing Chronic Myelogenous Leukemia|Small Intestine Lymphoma|Unspecified Childhood Solid Tumor, Protocol Specific | Drug: dexrazoxane hydrochloride|Drug: doxorubicin hydrochloride|Drug: obatoclax mesylate|Drug: liposomal vincristine sulfate|Other: pharmacological study|Other: laboratory biomarker analysis | National Cancer Institute (NCI) | Phase 1 | 2009-06-01 | 2014-04-30 |
| NCT00548704 | Extravasation | Drug: Dexrazoxane | Onxeo | Phase 2|Phase 3 | 2002-04-01 | 2015-10-20 |
| NCT00038142 | Ewing's Sarcoma | Drug: Vincristine|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Dexrazoxane|Biological: ImmTher | M.D. Anderson Cancer Center | Phase 2 | 1997-11-01 | 2016-03-03 |
| NCT00550901 | Unspecified Adult Solid Tumor, Protocol Specific | Drug: cisplatin|Drug: dexrazoxane hydrochloride|Other: high performance liquid chromatography|Other: laboratory biomarker analysis|Other: mass spectrometry|Other: pharmacological study | City of Hope Medical Center|National Cancer Institute (NCI) | Phase 1 | 2001-02-01 | 2015-06-03 |
| NCT00548561 | Anthracycline Extravasation | Drug: Dexrazoxane | Onxeo | Phase 2|Phase 3 | 2001-06-01 | 2015-10-20 |
| NCT00016276 | Cardiac Toxicity|Inflammatory Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IV Breast Cancer | Drug: dexrazoxane hydrochloride|Drug: doxorubicin hydrochloride|Drug: cyclophosphamide|Drug: paclitaxel|Biological: trastuzumab|Procedure: therapeutic conventional surgery|Radiation: radiation therapy|Drug: tamoxifen citrate|Other: laboratory biomarker analysis | National Cancer Institute (NCI) | Phase 3 | 2001-05-01 | 2013-01-15 |
| NCT01790152 | Recurrent Adult Hodgkin Lymphoma|Recurrent Adult T-Cell Leukemia/Lymphoma|Refractory Childhood Hodgkin Lymphoma|Stage I Adult Hodgkin Lymphoma|Stage I Adult T-Cell Leukemia/Lymphoma|Stage I Childhood Hodgkin Lymphoma|Stage II Adult Hodgkin Lymphoma|Stage II Adult T-Cell Leukemia/Lymphoma|Stage II Childhood Hodgkin Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult T-Cell Leukemia/Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult T-Cell Leukemia/Lymphoma|Stage IV Childhood Hodgkin Lymphoma | Other: Assessment of Therapy Complications|Other: Laboratory Biomarker Analysis|Other: Quality-of-Life Assessment|Other: Questionnaire Administration | Children's Oncology Group|National Cancer Institute (NCI) | | 2013-08-01 | 2016-10-24 |
| NCT00002827 | Cardiac Toxicity|Lymphoma | Biological: bleomycin sulfate|Biological: filgrastim|Drug: dexrazoxane hydrochloride|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: vincristine sulfate|Radiation: low-LET cobalt-60 gamma ray therapy|Radiation: low-LET electron therapy|Radiation: low-LET photon therapy | Children's Oncology Group|National Cancer Institute (NCI)|Children's Cancer Group | Phase 3 | 1996-10-01 | 2013-08-22 |
| NCT00003937 | Cardiac Toxicity|Sarcoma | Drug: cisplatin|Drug: dexrazoxane hydrochloride|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: methotrexate|Procedure: conventional surgery | Children's Oncology Group|National Cancer Institute (NCI) | Phase 3 | 1999-09-01 | 2014-08-04 |
| NCT00005578 | Cardiac Toxicity|Lymphoma | Biological: bleomycin sulfate|Biological: filgrastim|Drug: cyclophosphamide|Drug: dexrazoxane hydrochloride|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: prednisone|Drug: vincristine sulfate|Radiation: radiation therapy | Children's Oncology Group|National Cancer Institute (NCI) | Phase 3 | 1997-03-01 | 2014-07-23 |
| NCT00039481 | Cardiac Toxicity|Unspecified Childhood Solid Tumor, Protocol Specific | Biological: oblimersen sodium|Drug: dexrazoxane hydrochloride|Drug: doxorubicin hydrochloride|Drug: cyclophosphamide|Biological: filgrastim|Other: laboratory biomarker analysis|Other: pharmacological study | National Cancer Institute (NCI) | Phase 1 | 2002-11-01 | 2013-01-16 |
| NCT00544778 | Sarcoma | Biological: filgrastim|Drug: dexrazoxane hydrochloride|Drug: doxorubicin hydrochloride|Drug: ifosfamide|Drug: irinotecan hydrochloride|Genetic: protein expression analysis|Other: immunoenzyme technique|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy | City of Hope Medical Center|National Cancer Institute (NCI) | Phase 2 | 2001-08-01 | 2014-08-19 |
| NCT01230983 | Cardiac Toxicity|Leukemia|Lymphoma | Drug: asparaginase|Drug: cytarabine|Drug: dexrazoxane hydrochloride|Drug: doxorubicin hydrochloride|Drug: leucovorin calcium|Drug: mercaptopurine|Drug: methotrexate|Drug: prednisone|Drug: therapeutic hydrocortisone|Drug: vincristine sulfate|Radiation: radiation therapy | Children's Oncology Group|National Cancer Institute (NCI) | Phase 3 | 1996-06-01 | 2013-06-04 |
| NCT01696669 | Ewing's Sarcoma | Drug: Chemotherapy|Procedure: Surgery|Radiation: Radiotherapy | Grupo Espanol de Investigacion en Sarcomas | Phase 2 | 2010-04-01 | 2015-08-17 |
| NCT01185964 | Sarcoma, Soft Tissue | Biological: IMC-3G3|Drug: doxorubicin|Drug: dexrazoxane | Eli Lilly and Company | Phase 1|Phase 2 | 2010-10-01 | 2015-02-13 |
